Skip to main content

Ovarian Epithelial Carcinoma clinical trials at UCSF

4 in progress, 2 open to eligible people

Ovarian epithelial carcinoma is cancer found in the outer layer of the ovaries. UCSF is examining a new medicine's safety and effectiveness in treating advanced cancer. UCSF is also comparing two models that use technology to deliver supportive care to cancer patients.

Showing trials for
  • NX-1607 in Adults With Advanced Malignancies

    open to eligible people ages 18 years and up

    This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

    San Francisco, California and other locations

  • Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

    open to eligible people ages 18 years and up

    This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.

    San Francisco, California and other locations

  • Beta-only IL-2 ImmunoTherapY Study

    Sorry, not currently recruiting here

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    San Francisco, California and other locations

  • AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

    Sorry, in progress, not accepting new patients

    This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.

    San Francisco, California and other locations

Our lead scientists for Ovarian Epithelial Carcinoma research studies include .

Last updated: